Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 10/20 | 0.52 |
| ▸ | RARB | P10826 | 4/20 | 0.46 |
| ▸ | RARA | P10276 | 3/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488942 | 1.00 | CTPS1 (0.52) | CTPS1RARBRARAPIM1PIM3 | |
| SCHEMBL29489046 | 0.89 | CTPS1 (0.51) | CTPS1PIM1PIM3PIM2CYP11B2 | |
| SCHEMBL21392101 | 0.88 | CTPS1 (0.53) | CTPS1CYP11B2CYP11B1 | |
| SCHEMBL29489098 | 0.88 | CTPS1 (0.53) | CTPS1CYP11B2CYP11B1 | |
| SCHEMBL24088660 | 0.86 | NEK2 (0.46) | CTPS1RARBPIM1PIM3PIM2 | |
| SCHEMBL21392128 | 0.86 | CTPS1 (0.53) | CTPS1PIM1PIM3PIM2CYP11B2 | |
| SCHEMBL30455860 | 0.86 | CYP11B2 (0.49) | CTPS1RARBRARAPIM1PIM3 | |
| SCHEMBL30416932 | 0.86 | CTPS1 (0.53) | CTPS1PIM1PIM3PIM2CYP11B2 | |
| SCHEMBL24088759 | 0.86 | CYP11B2 (0.49) | CTPS1RARBRARAPIM1PIM3 | |
| SCHEMBL24369832 | 0.83 | CTPS1 (0.49) | CTPS1CYP11B2CYP11B1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263407-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-08-21 | — | — | US | disclosed |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12319680-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-06-03 | — | — | US | disclosed |
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| EP-4232425-A1 | CTPS1 INHIBITORS AND USES THEREOF | Nimbus Clotho, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116601131-A | CTPS1 inhibitor and application thereof | 林伯士克洛索有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022087634-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087634-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885RARB 885/4885RARA 1115/4885 |
| US-12319680-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885RARB 885/4885RARA 1115/4885 |
| US-20250263407-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885RARB 761/4885RARA 947/4885 |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | CTPS1 1/4885RARB 4139/4885RARA 4465/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885RARB 761/4885RARA 947/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885RARB 885/4885RARA 1115/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885RARB 761/4885RARA 947/4885 |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | CTPS1, CTPS2, ECHS1 | CTPS1 1/4885RARB 4139/4885RARA 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.